Gastaut H, Tinuper P, Aguglia U, Lugaresi E
Rev Electroencephalogr Neurophysiol Clin. 1984 Dec;14(3):203-6. doi: 10.1016/s0370-4475(84)80005-2.
The authors administered clobazam (CLB) to treat status epilepticus in 16 patients from 3 to 62 years old. Status epilepticus was of absence type (6 cases), myoclonic-absence type (1 case), myoclonic type (1 case), tonic (1 case) and elementary or complex partial (7 cases). In all patients consciousness was sufficiently retained to allow ingestion of the drug. CLB administration was performed under EEG monitoring, in a single oral dose averaging 1.0 mg/kg. In 15 patients, the status was stopped after a period ranging from 19 to 31 min without significant sedation or other side effects. In one patient a somatomotor status epilepticus, lasting 8 days, terminated 6 h after drug administration. It is well known that the efficacy of a drug on status epilepticus depends on the clinical context and semiological form of the status. Nevertheless, the authors conclude that the pharmacokinetic properties of CLB, its mild sedative effects and ease of administration, make this a useful drug in the management of some forms of status epilepticus.
作者对16例年龄在3至62岁的癫痫持续状态患者使用氯巴占（CLB）进行治疗。癫痫持续状态类型包括失神型（6例）、肌阵挛 - 失神型（1例）、肌阵挛型（1例）、强直型（1例）以及简单或复杂部分性发作型（7例）。所有患者意识均能充分保持以允许服用药物。CLB给药在脑电图监测下进行，单次口服剂量平均为1.0mg/kg。15例患者的癫痫持续状态在19至31分钟内停止，未出现明显镇静或其他副作用。1例患者的躯体运动性癫痫持续状态持续了8天，在给药6小时后终止。众所周知，一种药物对癫痫持续状态的疗效取决于癫痫持续状态的临床背景和发作形式。尽管如此，作者得出结论，CLB的药代动力学特性、其轻度镇静作用以及易于给药，使其成为治疗某些形式癫痫持续状态的有用药物。
